|
|
局部进展期胃癌新辅助治疗的研究现状
|
Abstract:
在我国，胃癌的早期发现及诊断率比较低，多数的胃癌患者出现症状而就诊时已发展为局部进展期；伴随着胃癌治疗模式的更新与进步，局部进展期胃癌(Local advanced gastric cancer, LAGC)的治疗模式已转变为多学科治疗的综合治疗模式，LAGC的新辅助治疗更是在其综合治疗中占据重要的地位。LAGC患者接受新辅助治疗，可使原肿瘤病症、隐匿的淋巴结缩小或消失，其肿瘤分期下降的几率升高，手术及根治性手术成功率提高，减少肿瘤手术后的复发率。进行新辅助治疗的肿瘤患者的体力、相关药物的耐受性等优于辅助治疗的患者，利于治疗周期很好的完成，从而为LAGC患者带来受益。
Early detection and diagnosis of gastric cancer are relatively low in our country, and most patients with gastric cancer develop local progression when they show symptoms and attend a clinic. With the update and progression of gastric cancer treatment models, the local advanced gastric cancer (LAGC) treatment model has been transformed into a multidisciplinary approach to combination therapy, and new adjuvant therapies for LAGC occupy a significant place in its portfolio. In LAGC pa-tients undergoing neoadjuvant therapy, tumor stage decreased, tumor lesions and hidden lymph nodes shrank or disappeared, increasing surgical and radical surgical success and reducing recur-rence after tumor surgery. Patients with neoadjuvant therapy have better physical strength and re-sistance to associated drugs than patients with adjuvant therapy, enabling a good completion of the treatment cycle, thus benefiting LAGC patients.
| [1] | He, Y., Wang, Y., Luan, F., et al. (2021) Chinese and Global Burdens of Gastric Cancer from 1990 to 2019. Cancer Medicine, 10, 3461-3473. https://doi.org/10.1002/cam4.3892 |
| [2] | Wang, Y., Lei, X., Liu, Z., et al. (2021) Short-Term Outcomes of Laparoscopic versus Open Total Gastrectomy after Neoadjuvant Chemotherapy: A Cohort Study Using the Propensity Score Matching Method. Journal of Gastrointestinal Oncology, 12, 237-248. https://doi.org/10.21037/jgo-20-374 |
| [3] | Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van de Velde, C.J., Nicolson, M., Scarffe, J.H., Lofts, F.J., Falk, S.J., Iveson, T.J., Smith, D.B., Langley, R.E., Verma, M., Weeden, S., Chua, Y.J. and MAGIC Trial Participants (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20. https://doi.org/10.1056/NEJMoa055531 |
| [4] | Wilke, H., Preusser, P., Fink, U., Gunzer, U., Meyer, H.J., Meyer, J., Siewert, J.R., Achterrath, W., Lenaz, L., Knipp, H., et al. (1989) Preoperative Chemotherapy in Locally Advanced and Nonresectable Gastric Cancer: A Phase II Study with Etoposide, Doxorubicin, and Cisplatin. Journal of Clinical Oncol-ogy, 7, 1318-1326.
https://doi.org/10.1200/JCO.1989.7.9.1318 |
| [5] | Al-Batran, S.E., Homann, N., Pauligk, C., et al. (2019) Periopera-tive Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957. |
| [6] | National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines*): Gastric Cancer (Version 2. 2018). https://www.nccn.org |
| [7] | Ito, S., Sano, T., Mizusawa, J., et al. (2017) A Phase II Study of Preoperative Chemo-therapy with Docetaxel, Cisplatin, and S-1 Followed by Gastrectomy with D2 plus Para-Aortic Lymphnode Dissection for Gastric Cancer with Extensive Lymphnode Metastasis: JCOG1002. Gastric Cancer, 20, 322-331. https://doi.org/10.1007/s10120-016-0619-z |
| [8] | Wang, F.H., Shen, L., Li, J., et al. (2019) The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer. Cancer Communica-tions, 39, 10.
https://doi.org/10.1186/s40880-019-0349-9 |
| [9] | 中国抗癌协会胃癌专业委员会. 局部进展期胃癌围手术期治疗中国专家共识(2021版) [J]. 中华胃肠外科杂志, 2021, 24(9): 741-748. https://doi.org/10.3760/cma.j.cn.441530-20210831-00351 |
| [10] | Macdonald, J.S., Smalley, S.R., Benedetti, J., et al. (2001) Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gas-troesophageal Junction. The New England Journal of Medicine, 345, 725-730. https://doi.org/10.1056/NEJMoa010187 |
| [11] | Ajani, J.A., Winter, K., Okawara, G.S., et al. (2006) Phase II Trial of Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. Journal of Clinical Oncology, 24, 3953-3958. https://doi.org/10.1200/JCO.2006.06.4840 |
| [12] | Ajani, J.A., Walsh, G., Komaki, R., et al. (2004) Preoperative In-duction of CPT-11 and Cisplatin Chemotherapy Followed by Chemoradiotherapy in Patients with Locoregional Carci-noma of the Esophagus or Gastroesophageal Junction. Cancer, 100, 2347-2354. https://doi.org/10.1002/cncr.20284 |
| [13] | Shapiro, J., van Lanschot, J., Hulshof, M., et al. (2015) Neoadjuvant Chemoradiotherapy plus Surgery versus Surgery Alone for Oesophageal or Junctional Cancer (CROSS): Long-Term Results of a Randomised Controlled Trial. The Lancet Oncology, 16, 1090-1098. |
| [14] | Stahl, M., Walz, M.K., Stuschke, M., et al. (2009) Phase III Comparison of Preoperative Chemotherapy Compared with Chemoradiotherapy in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction. Journal of Clinical Oncology, 27, 851-856. https://doi.org/10.1200/JCO.2008.17.0506 |
| [15] | Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumabin Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
https://doi.org/10.1016/S0140-6736(10)61121-X |
| [16] | Hofheinz, R.D., Hegewisch-Becker, S., Kunzmann, V., et al. (2021) Trastuzumab in Combination with 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel as Perioperative Treat-ment for Patients with Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Esophagogastric Adeno-Carcinoma: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International Journal of Cancer, 149, 1322-1331.
https://doi.org/10.1002/ijc.33696 |
| [17] | Hacker, U.T., Escalona-Espinosa, L., Consalvo, N., et al. (2016) Evaluation of Angiopoietin-2 as a Biomarker in Gastric Cancer: Results from the Randomised Phase III AVAGAST Trial. British Journal of Cancer, 114, 855-862.
https://doi.org/10.1038/bjc.2016.30 |
| [18] | Cunningham, D., Stenning, S.P., Smyth, E.C., et al. (2017) Peri-Operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma (UK Medical Research Council ST03): Primary Analysis Results of a Multicentre, Open-Label, Randomised Phase 2-3 Trial. The Lancet On-cology, 18, 357-370.
https://doi.org/10.1016/S1470-2045(17)30043-8 |
| [19] | Fuchs, C.S., Muro, K., Tomasek, J., et al. (2017) Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-Line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. Journal of Gastric Cancer, 17, 132-144. https://doi.org/10.5230/jgc.2017.17.e16 |
| [20] | Boku, N., Satoh, T., Ryu, M.H., Chao, Y., et al. (2021) Nivolumab in Previously Treated Advanced Gastric Cancer (ATTRACTION-2): 3-Year Update and Outcome of Treatment beyond Progression with Nivolumab. Gastric Cancer, 24, 946-958. https://doi.org/10.1007/s10120-021-01173-w |
| [21] | Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Effi-cacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junc-tion Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013. |
| [22] | Fukuoka, S., Hara, H., Takahashi, N., et al. (2020) Regorafenib plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical On-cology, 38, 2053-2061. https://doi.org/10.1200/JCO.19.03296 |
